Mood stabilizer combinations: A review of safety and efficacy

American Journal of Psychiatry

Volumn 155, Issue 1, 1998, Pages 12-21

  Freeman, Marlene P ^a   Stoll, Andrew L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL AFFECTING AGENT; CARBAMAZEPINE; CLOZAPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; OLANZAPINE; RISPERIDONE; VALPROIC ACID;

DIABETIC KETOACIDOSIS; DROWSINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; TREMOR;

EID: 0031985493     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.1.12     Document Type: Review

References (121)

1. Nichol MB, Stimmel GL, Lange SC: Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry 1995; 56:60-66
2. Frances A, Docherty JP, Kahn DA: Treatment of bipolar disorder. J Clin Psychiatry 1996; 57(suppl 12A):5-58
3. Fenn HH, Robinson D, Luby V, Dangel C, Buxton E, Beattie M, Kraemer H, Yesavage JA: Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996; 153:711-713
4. Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea T, Kazim A, Keller MB: A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58:95-99
5. Sharma V, Persad E, Mazmanian D, Karunaratne K: Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993; 38:137-139
6. Schaff M, Fawcett J, Zajecka J: Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993; 54:380-384
7. Sharma V, Persad E: Augmentation of valproate with lithium in a case of rapid cycling affective disorder. Can J Psychiatry 1992; 37:584-585
8. Mitchell P, Withers K, Jacobs G, Hickie I: Combining lithium and sodium valproate for bipolar disorder. Aust NZ J Psychiatry 1994; 28:141-143
9. Lenox RH, McNamara RK, Watterson JM, Watson DG: Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996; 57(suppl 13):23-31
10. Granneman GR, Schneck DW, Cavanaugh JH, Witt GF: Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry 1996; 57:204-206
11. Di Costanzo E, Schifano F: Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand 1991; 83:456-459
12. Kramlinger K, Post R: Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 1989; 79:378-385
13. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ: Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995; 31:265-272
14. Kishimoto A: The treatment of affective disorder with carbamazepine: prophylactic synergism of lithium and carbamazepine combination. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:483-493
15. Shukla S, Cook BL, Miller MG: Lithium-carbamazepine versus lithium-neuroleptic prophylaxis in bipolar illness. I Affect Disord 1985; 9:219-222
16. Inoue K, Arima S, Tanaka K, Fukui Y, Kato N: A lithium and carbamazepine combination in the treatment of bipolar disorder - a preliminary report. Folia Psychiatr Neurol Jpn 1981; 35:465-475
17. Stromgren LS: The combination of lithium and carbamazepine in treatment and prevention of manic-depressive disorder: a review and a case report. Compr Psychiatry 1990; 31:261-265
18. Lipinski JF, Pope HG Jr: Possible synergistic action between carbamazepine and lithium carbonate in the treatment of three acutely manic patients. Am J Psychiatry 1982; 139:948-949
19. Brewerton T: Lithium counteracts carbamazepine-induced leucopenia while increasing its therapeutic effect. Biol Psychiatry 1996; 21:677-685
20. Joffe R: Hematological effects of lithium potentiation of carbamazepine in patients with affective illness. Int Clin Psychopharmacol 1988; 3:53-57
21. Sheehan J, Shelley R: Leucopenia secondary to carbamazepine despite concurrent lithium treatment. Br J Psychiatry 1990; 157:911-912
22. Chaudhry RP, Waters BG: Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983; 44:30-31
23. Rittmannsberger H, Leblhuber F: Asterixis induced by carbamazepine therapy. Biol Psychiatry 1992; 32:364-368
24. Shukla S, Godwin CD, Long LEB, Miller MG: Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984; 141:1604-1606
25. Helmuth D, Ljaljevic Z, Ramirez L, Meltzer H: Choreoathetosis induced by verapamil and lithium treatment. J Clin Psychopharmacol 1989; 9:454-455
26. Finley P, Warner M, Peabody C: Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29:172-191
27. Wright B, Jarrett D: Lithium and calcium channel blockers: possible neurotoxicity. Biol Psychiatry 1991; 30:635-636
28. Dubovsky SL, Franks RD, Allen S: Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry 1987; 48:371-372
29. Weinrauch LA, Belok S, D'Elia J: Decreased serum lithium during verapamil therapy. Am Heart J 1984; 108:1378-1380
30. Valdiserri EV: A possible interaction between lithium and diltiazem: case report. J Clin Psychiatry 1985; 46:540-541
31. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE: Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986; 148:723-725
32. Juhl RP, Tsuang MT, Perry PJ: Concomitant administration of haloperidol and lithium carbonate in acute mania. Dis Nerv Syst 1977; 38:675-676
33. Goldney RD, Spence ND: Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 1986; 143:882-884
34. Krishna NR, Taylor MA, Abrams R: Combined haloperidol and lithium carbonate in treating manic patients. Compr Psychiatry 1978; 19:119-120
35. Perenyi A, Rihmer Z, Banki C: Parkinsonian symptoms with lithium, lithium-neuroleptic, and lithium-antidepressant treatment. J Affect Disord 1983; 5:171-177
36. Miller F, Menninger J: Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol 1987; 7:89-91
37. Baastrup PC, Hollnagel P, Sorensen R, Schou M: Adverse reactions in treatment with lithium carbonate and haloperidol. JAMA 1976; 236:2645-2646
38. Garfinkel PE, Stancer HC, Persad E: A comparison of haloperidol, lithium carbonate, and their combination in the treatment of mania. J Affect Disord 1980; 2:279-288
39. Carman JS, Bigelow LB, Wyatt RJ: Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981; 42:124-128
40. Ghadirian AM, Nair NP, Schwartz G: Effect of lithium and neuroleptic combination on lithium transport, blood pressure, and weight in bipolar patients. Biol Psychiatry 1989; 26:139-144
41. Loew MR: Rapid cycling disorders and the role of combined lithium and haloperidol decanoate. Can J Psychiatry 1986; 31:877-878
42. Bigelow LB, Weinberger DR, Wyatt RJ: Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study. Am J Psychiatry 1981; 138:81-83
43. Miller F, Menninger J, Whitcup S: Lithium-neuroleptic neurotoxicity in the elderly bipolar patient. J Clin Psychopharmacol 1986; 6:176-178
44. Spring G: Neurotoxicity with combined use of lithium and thioridazine. J Clin Psychiatry 1979; 40:135-138
45. Mani J, Tandel S, Shah P, Karnad D: Prolonged neurological sequelae after combination treatment with lithium and antipsychotic drugs. J Neurosurg Psychiatry 1996; 60:350-351
46. Byrne A, Zibin T, Chimich W, Hnatko G: Severe hypotension associated with combined lithium and chlorpromazine therapy: a case report and a review. Can J Psychiatry 1994; 39:294-296
47. Menes C, Burra P, Hoaken P: Untoward effects following combined neuroleptic-lithium therapy: cardiac arrhythmias and seizure. Can J Psychiatry 1980; 25:573-576
48. Cohen WJ, Cohen NH: Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 1974; 230:1283-1287
49. Marhold J, Zimanova J, Lachman M, Kral J, Vojtechovsky M: To the incompatibility of haloperidol with lithium salts. Act Nerv Super (Praha) 1974; 16:199-200
50. London JB, Waring H: Toxic reactions to lithium and haloperidol (letter). Lancet 1976; 2:1088
51. Mann SC, Greenstein RA, Eilers R: Early onset of severe dyskinesia following lithium-haloperidol treatment (letter). Am J Psychiatry 1983; 140:1385-1386
52. Spring G, Frankel M: New data on lithium and haloperidol incompatibility. Am J Psychiatry 1981; 138:818-821
53. Dinan T, Kohen D: Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Br J Psychiatry 1989; 155:55-57
54. Perenyi A, Szucs R, Frecska E: Tardive dyskinesia in patients receiving lithium maintenance therapy. Biol Psychiatry 1984; 19:1573-1578
55. Goodwill J, Jamison KR: Manic Depressive Illness. New York, Oxford University Press, 1990
56. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY: Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759-764
57. McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O'Brien S: Clozapine in the treatment of psychotic mood disorders, schizoaffectivc disorder, and schizophrenia. J Clin Psychiatry 1991; 52:411-414
58. Zarate CA Jr, Tohen M, Baldessarini RJ: Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411-417
59. Zarate CA Jr, Tohen M, Banov MP, Weiss MK, Cole JO: Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56:108-112
60. Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY: Clozapine in treatment-refractory mood disorders. J Clin Psychiatry 1994; 55(Sept suppl B):91-93
61. Banov MD, Zarate C Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M, Kim JW, Cole JO: Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55:295-300
62. Suppes T, Phillips KA, Judd CR: Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994; 136:338-340
63. Puri BK, Taylor DG, Alcock ME: Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder. Br J Clin Pract 1995; 49:333-334
64. Fuchs DC: Clozapine treatment of bipolar disorder in a young adolescent. J Am Acad Child Adolesc Psychiatry 1994; 33:1299-1302
65. Blake LM, Marks RC, Luchins DJ: Reversible neurologic symptoms with clozapine and lithium. J Clin Psychopharmacol 1992; 12:297-299
66. Garcia G, Crismon M, Dorson P: Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 1994; 14:426-428
67. Lemus C, Lieberman J, Johns C: Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry 1989; 11:127-130
68. Peterson GA, Byrd SL: Diabetic ketoacidosis from clozapine and lithium cotreatment (letter). Am J Psychiatry 1996; 153:737-738
69. Pope HG Jr, Cole JO, Choras PT, Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174:493-495
70. Adityanjee: Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate (letter). Am J Psychiatry 1995; 152:648-649
71. Valevski A, Modai I, Lahav M, Weizman A: Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 1993; 8:63-65
72. Tohen M, Zarate CA Jr, Centorrino F, Hegarty JI, Froeschl M, Zarate SB: Risperidone in the treatment of mania. J Clin Psychiatry 1996; 57:249-253
73. Ghaemi SN, Sachs GS, Baldassano CF, Truman CJ: Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry 1997; 42:196-199
74. Swanson CL Jr, Price WA, McEvoy JP: Effects of concomitant risperidone and lithium treatment (letter). Am J Psychiatry 1995; 152:1096
75. Chen B, Cardasis W: Delirium induced by lithium and risperidone combination (letter). Am J Psychiatry 1996; 153:1233-1234
76. Aronson TA, Shukla S, Hirschowitz J: Clonazepam treatment of five lithium-refractory patients with bipolar disorder. Am J Psychiatry 1989; 146:77-80
77. Sachs GS, Rosenbaum JF, Jones L: Adjunctive clonazepam for maintenance treatment of bipolar affective disorder. J Clin Psychopharmacol 1990; 10:42-47
78. Sachs GS, Weilburg JB, Rosenbaum JF: Clonazepam vs neuroleptics as adjuncts to lithium maintenance. Psychopharmacol Bull 1990; 26:137-143
79. Adler LW: Mixed bipolar disorder responsive to lithium and clonazepam. J Clin Psychiatry 1986; 47:49-50
80. Modell JG, Lenox RH, Weiner S: Inpatient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol 1985; 5:109-113
81. Koczerginski D, Kennedy SH, Swinson RP: Clonazepam and lithium - a toxic combination in the treatment of mania? Int Clin Psychopharmacol 1989; 4:195-199
82. Schaffer CB, Schaffer LC: Gabapentin in the treatment of bipolar disorder (letter). Am J Psychiatry 1997; 154:291-292
83. Stanton SP, Keck PE Jr, McElroy SL: Treatment of acute mania with gabapentin (letter). Am J Psychiatry 1997; 154:287
84. Vollmer KO, Von Hodenberg A, Kolle EU: Pharmacokinetics and metabolism of gabapentin in rat, dog, and man. Arzneimittelforschung 1986; 36:830-839
85. Calabrese JR, Fatemi SH, Woyshville MJ: Antidepressant effects of lamotrigine in rapid cycling bipolar disorder (letter). Am J Psychiatry 1996; 153:1236
86. Calabrese J, Bowden C, McElroy S, Cookson J, Anderson J, Rhodes L, Woychville M, Keck P, Kundu F, Patterson G, Ascher J, Golden-Watson C: Efficacy of lamotrigine in bipolar disorder: preliminary data, in Mechanisms of Antibipolar Disorder Treatments. Edited by Manji H, Bowden C, Belmaker R. Washington, DC, American Psychiatric Press (in press)
87. Tohen M, Castillo J, Pope HG Jr, Herbstein J: Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14:67-70
88. Ketter TA, Pazzaglia PJ, Post RM: Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992; 12:276-281
89. Levy RH: Cytochrome P450 isoenzymes and antiepileptic drug interactions. Epilepsia 1995; 36(5, suppl):S8-S13
90. Sovner R: A clinically significant interaction between carbamazepine and valproic acid. J Clin Psychopharmacol 1988; 8:448-449
91. Onady AA, Calabrese JR: Carbamazepine auto- and hetero-induction complicating clinical care. J Clin Psychopharmacol 1989; 9:387-388
92. Wassef A, Watson DJ, Morrison P, Bryant S, Flack J: Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989; 9:45-48
93. Van Sweden B, Van Moffaert M: Valproate as psychotropic agent: interactions and adverse cerebral reactions. Acta Psychiatr Scand 1985; 72:315-317
94. Kando JC, Tohen M, Castillo J, Centorrino F: Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55:255-25
95. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG: Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxerine or valproate. Am J Psychiatry 1994; 151:123-125
96. Longo LP, Salzman C: Valproic acid effects on serum concentrations of clozapine and norclozapine (letter). Am J Psychiatry 1995; 152:650
97. Costello L, Suppes T: A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 1995; 15:139-140
98. Wilson W: Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 1995; 37:132-133
99. Graham SR, Kokkinidis L: Clozapine inhibits limbic system kindling: implications for antipsychotic action. Brain Res Bull 1993; 30:597-605
100. Peck WA: Clinical pharmacology of lamotrigine. Epilepsia 1991; 32(suppl 2):S9-S12
101. Eriksson AS, Hoppu K, Nergardh A, Boreus L: Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996; 37:769-773
102. Pisani F, Di Perri R, Perucca E, Richens A: Interaction of lamotrigine with sodium valproate (letter). Lancet 1993; 341:1224
103. Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO: Interaction of lamotrigine with sodium valproate (letter). Lancet 1993; 341:445
104. Yeun A, Land G, Weatherley B, Peck A: Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33:511-513
105. Reutens DC, Duncan JC, Patsalos PN: Disabling tremor after lamotrigine with sodium valproate. Lancet 1993; 342:185-186
106. Anderson G, Yau M, Gidal B, Harris S, Levy R, Lai A, Wolf K, Wargin W, Dren A: Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60:145-156
107. Radulovic LL, Wilder BJ, Leppik IE, Bockbrader HN, Chang T, Posvar EL, Sedman AJ, Uthman BM, Erdman GR: Lack of interaction of gabapentin with carbamazepine or valproate. Epilepsia 1994; 35:155-161
108. Junghan U, Albers M, Woggon B: Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? (letter). Pharmacopsychiatry 1993; 26:262
109. Tiihoncn J, Vartiainen H, Hakola P: Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995; 28:26-28
110. Raitasuo V, Lehtovaara R, Huttunen MO: Carbamazepine and plasma levels of clozapine (letter). Am J Psychiatry 1993; 150:169
111. Müller T, Becker T, Fritze J: Neuroleptic malignant syndrome after clozapine plus carbamazepine (letter). Lancet 1988; 2:1500
112. Fast DK, Jones BD, Kusalic M, Erickson M: Effect of carbamazepine on neuroleptic plasma levels and efficacy (letter). Am J Psychiatry 1986; 143:117-118
113. Ereshefsky L, Davis CM, Harrington CA, Jann MW, Browning JL, Saklad SR, Burch NR: Haloperidol and reduced haloperidol levels in selected schizophrenic patients. J Clin Psychopharmacol 1984; 4:138-142
114. Gadde K, Calabrese JR: Diltiazem effect of carbamazepine levels in manic depression. J Clin Psychopharmacol 1990; 10:378-379
115. Price WA, DiMarzio LR: Verapamil-carbamazepine neurotoxicity (letter). J Clin Psychiatry 1988; 49:80
116. MacPhee GJ, McInnes GT, Thompson GG, Brodie MJ: Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986; 29:700-703
117. Bahls FH, Ozuna J, Ritchie DE: Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 1991; 41:740-742
118. Pisani F, Xiao B, Fazio A, Spina E, Perucca E, Tomson T: Single dose pharmacokinetics of carbamazepine-10,11 -epoxide in patients on lamotrigine monotherapy. Epilepsy Res 1994; 19:245-248
119. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS: Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11:147-150
120. Keck PE Jr, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, Bennett JA, Tugrul KC, West SA: Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996; 57:292-297
121. Stoll AL, Severus K: Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes. Harvard Rev Psychiatry 1996; 4:77-89